Hepatitis C News

Experts are warning that it is not a matter of if, but when, the next pandemic strikes.

BETHESDA, Maryland — In this exclusive video from the AASLD Industry Colloquium 2018, Kris V. Kowdley, MD, FAASLD, from Swedish Medical Center in Seattle, Washington, discusses the topics covered at the meeting and the opportunities for representatives of the industry, academia and regulatory agencies to come together.

Ravidasvir plus ritonavir-boosted danoprevir with ribavirin for 12 weeks resulted in 100% sustained virologic response among a cohort of Asian patients with hepatitis C genotype 1 without cirrhosis, according to recently published results of a phase 2 study.

Results of a comparative study of patients with and without diabetes who underwent curative liver resection for hepatitis C-related hepatocellular carcinoma showed that diabetes did not affect surgical outcomes and was not an unfavorable factor in selecting candidates.

Patients who underwent liver transplantation evaluation had a high prevalence of coronary artery disease, especially those with nonalcoholic steatohepatitis-related cirrhosis, hepatitis C-related cirrhosis and alcoholic cirrhosis, according to a recently published study.

The safety and efficacy of Viekirax was comparable between patients with hepatitis C genotype 1b and chronic kidney disease and those without chronic kidney disease, according to a recently published study.

In patients with hepatitis C virus infection who were receiving opioid substitutes, interferon-free drug regimens yielded better outcomes compared with regimens containing interferon, according to researchers.

Patients with chronic hepatitis B virus infection who discontinued the antiviral tenofovir faced a significantly earlier relapse compared with those who discontinued entecavir, researchers in Taiwan reported.

Data from a clinical trial showed that Harvoni for 12 or 24 weeks with or without ribavirin was safe and effective in treatment-experienced patients with hepatitis genotype 1 with cirrhosis.

The HepCom score — which combines Charlson Comorbidity Index, age, international normalized ratio, albumin and bilirubin — accurately detected patients with hepatitis C at high risk for 1- and 2-year mortality after the start of direct-acting antiviral therapy, according to recently published data.